TWI814187B - 使用ACTRII配位體捕捉以治療β-地中海型貧血 - Google Patents

使用ACTRII配位體捕捉以治療β-地中海型貧血 Download PDF

Info

Publication number
TWI814187B
TWI814187B TW110148304A TW110148304A TWI814187B TW I814187 B TWI814187 B TW I814187B TW 110148304 A TW110148304 A TW 110148304A TW 110148304 A TW110148304 A TW 110148304A TW I814187 B TWI814187 B TW I814187B
Authority
TW
Taiwan
Prior art keywords
certain embodiments
actriib
individual
signaling inhibitor
seq
Prior art date
Application number
TW110148304A
Other languages
English (en)
Chinese (zh)
Other versions
TW202231294A (zh
Inventor
肯尼斯 M 艾堤
艾德拉曼 拉丹
拉傑許 喬普拉
傑 貝克斯壯
Original Assignee
美商西建公司
美商艾瑟勒朗法瑪公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商西建公司, 美商艾瑟勒朗法瑪公司 filed Critical 美商西建公司
Publication of TW202231294A publication Critical patent/TW202231294A/zh
Application granted granted Critical
Publication of TWI814187B publication Critical patent/TWI814187B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW110148304A 2015-05-13 2016-05-12 使用ACTRII配位體捕捉以治療β-地中海型貧血 TWI814187B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562161136P 2015-05-13 2015-05-13
US62/161,136 2015-05-13
US201562173836P 2015-06-10 2015-06-10
US62/173,836 2015-06-10
US201562243457P 2015-10-19 2015-10-19
US62/243,457 2015-10-19

Publications (2)

Publication Number Publication Date
TW202231294A TW202231294A (zh) 2022-08-16
TWI814187B true TWI814187B (zh) 2023-09-01

Family

ID=57248528

Family Applications (2)

Application Number Title Priority Date Filing Date
TW110148304A TWI814187B (zh) 2015-05-13 2016-05-12 使用ACTRII配位體捕捉以治療β-地中海型貧血
TW105114763A TWI762444B (zh) 2015-05-13 2016-05-12 使用ＡＣＴＲＩＩ配位體捕捉以治療β-地中海型貧血

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW105114763A TWI762444B (zh) 2015-05-13 2016-05-12 使用ＡＣＴＲＩＩ配位體捕捉以治療β-地中海型貧血

Country Status (15)

Country Link
US (1) US20180125928A1 (cg-RX-API-DMAC7.html)
EP (1) EP3294320A4 (cg-RX-API-DMAC7.html)
JP (2) JP6976859B2 (cg-RX-API-DMAC7.html)
KR (1) KR102640198B1 (cg-RX-API-DMAC7.html)
CN (1) CN107847562A (cg-RX-API-DMAC7.html)
AU (2) AU2016261913B2 (cg-RX-API-DMAC7.html)
CA (1) CA2985777A1 (cg-RX-API-DMAC7.html)
HK (1) HK1251157A1 (cg-RX-API-DMAC7.html)
IL (2) IL284686B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20160092B1 (cg-RX-API-DMAC7.html)
MY (1) MY189601A (cg-RX-API-DMAC7.html)
PH (1) PH12017502079A1 (cg-RX-API-DMAC7.html)
TN (1) TN2017000468A1 (cg-RX-API-DMAC7.html)
TW (2) TWI814187B (cg-RX-API-DMAC7.html)
WO (1) WO2016183280A1 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612041B2 (en) 2005-11-23 2009-11-03 Acceleron Pharma Inc. Isolated activin-binding ActRIIa polypeptide comprising the SEQ ID NO: 7 and uses for promoting bone growth
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
US8058229B2 (en) 2008-08-14 2011-11-15 Acceleron Pharma Inc. Method of increasing red blood cell levels or treating anemia in a patient
CN102482339B (zh) 2009-06-08 2015-06-17 阿塞勒隆制药公司 用于增加产热脂肪细胞的方法
CN107267520A (zh) 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
US8710016B2 (en) 2009-11-17 2014-04-29 Acceleron Pharma, Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
AU2013337677B2 (en) 2012-11-02 2018-06-28 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
BR122023023170A2 (pt) 2014-06-13 2024-02-20 Acceleron Pharma Inc. Uso de um antagonista de actrii no tratamento ou prevenção de úlcera cutânea associada com beta-talassemia
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
CN107533040B (zh) 2014-12-03 2022-03-29 细胞基因公司 激活素-actrii拮抗剂及用于治疗贫血症的用途
JP2018522579A (ja) 2015-05-20 2018-08-16 セルジーン コーポレイション アクチビンＩＩ型受容体リガンドトラップを使用するβ−サラセミアのインビトロ細胞培養法
EP3370754A4 (en) 2015-11-04 2019-10-23 Acceleron Pharma Inc. METHOD FOR INCREASING ERYTHROCYTE CONCENTRATION AND TREATMENT OF INEFFICIENT ERYTHROPOIESE
WO2017091706A1 (en) 2015-11-23 2017-06-01 Acceleron Pharma Inc. Methods for treating eye disorders
US10722558B2 (en) * 2016-07-15 2020-07-28 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
EA201990226A1 (ru) 2016-07-27 2019-08-30 Акселерон Фарма Инк. Способы и композиции для лечения миелофиброза
US11013785B2 (en) 2016-11-10 2021-05-25 Keros Therapeutics, Inc. Activin receptor type IIA variants and methods of use thereof
DK3638243T3 (da) * 2017-06-14 2024-10-28 Celgene Corp Fremgangsmåder til behandling af myeloproliferativ neoplasma-forbundet myelofibrose og anæmi
KR20200085832A (ko) 2017-11-09 2020-07-15 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법
CN120535607A (zh) 2018-01-12 2025-08-26 科乐斯疗法公司 激活素受体iib型变体及其使用方法
EP3788065B1 (en) 2018-04-30 2025-08-27 The Children's Hospital Of Philadelphia Improving anemias by combining agents
AU2019266314B2 (en) 2018-05-09 2025-05-15 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
KR20210088548A (ko) * 2018-10-31 2021-07-14 셀진 코포레이션 액티빈-actrii 리간드 트랩을 사용하는 고리 철적혈모구가 있는 대상체에서 매우 낮은, 낮은 또는 중간 위험 골수이형성 증후군으로 인한 빈혈의 치료
MX2022000782A (es) 2019-07-19 2022-04-18 Vifor Int Ag Inhibidores de la ferroportina para el uso en el tratamiento de la beta-talasemia dependiente de transfusiones (tdt).
CN112924684B (zh) * 2019-12-05 2022-07-29 中国科学院大连化学物理研究所 用于区分抑郁症和非抑郁症的生物标志物和包括其的诊断试剂盒
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
BR112022020628A2 (pt) * 2020-04-13 2022-11-29 Celgene Corp Métodos para tratamento de anemia usando uma armadilha de ligante de actriib e fedratinibe
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof
EP4240399A4 (en) * 2020-11-06 2024-10-09 Acceleron Pharma Inc. FORMULATIONS WITH ACTRII POLYPEPTIDE VARIANTS
US20240181007A1 (en) * 2021-01-08 2024-06-06 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
CA3205845A1 (en) 2021-01-20 2022-07-28 Francesca VINCHI Ferroportin-inhibitors for the use in the treatment of myelodysplastic syndromes (mds)
WO2025003139A1 (en) 2023-06-26 2025-01-02 Vifor (International) Ag Ferroportin-inhibitors for the use in the treatment of hereditary haemochromatosis (hh)
WO2025122830A1 (en) * 2023-12-08 2025-06-12 Keros Therapeutics, Inc. Methods of using activin receptor type ii signaling inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4247A (en) * 1845-11-01 Jordan l
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
EP2468290B1 (en) * 2006-12-18 2015-04-01 Acceleron Pharma, Inc. Activin-ActRII Antagonists for use in treating anemia
US20100015144A1 (en) * 2008-06-26 2010-01-21 Acceleron Pharma Inc. Methods for dosing an activin-actriia antagonist and monitoring of treated patients
US8058229B2 (en) * 2008-08-14 2011-11-15 Acceleron Pharma Inc. Method of increasing red blood cell levels or treating anemia in a patient
MX340451B (es) * 2009-09-09 2016-07-08 Acceleron Pharma Inc Antagonistas de actriib y dosificacion y usos de los mismos.
DK3520805T3 (da) * 2011-10-17 2021-04-19 Acceleron Pharma Inc Sammensætninger til behandling af myelofibrose
EP2830642B1 (en) * 2012-03-30 2019-08-28 Shire Human Genetic Therapies, Inc. Subcutaneous administration of iduronate- 2-sulfatase
WO2014066486A2 (en) * 2012-10-24 2014-05-01 Celgene Corporation Biomarker for use in treating anemia
US20150266950A1 (en) * 2012-10-24 2015-09-24 Celgene Corporation Methods for treating anemia
MX361412B (es) * 2012-11-27 2018-12-05 Childrens Medical Center Direccion de elementos reguladores distales de bcl11a para reinduccion de hemoglobina fetal.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 MD Cappellini, et al. "A Phase 2a, Open-Label, DoseFinding Study To Determine The Safety and Tolerability Of Sotatercept (ACE-011) In Adults With Beta (β)- Thalassemia: Interim Results" Blood 122(21):3448 2013 全文

Also Published As

Publication number Publication date
TN2017000468A1 (en) 2019-04-12
JP2018520094A (ja) 2018-07-26
IL284686B (en) 2023-01-01
WO2016183280A1 (en) 2016-11-17
AU2016261913A1 (en) 2017-11-30
AU2021258087A1 (en) 2021-11-25
CN107847562A (zh) 2018-03-27
MY189601A (en) 2022-02-18
HK1251157A1 (zh) 2019-01-25
IL284686B2 (en) 2023-05-01
KR102640198B1 (ko) 2024-02-23
IL284686A (en) 2021-08-31
PH12017502079A1 (en) 2018-06-11
TW201709927A (zh) 2017-03-16
JP6976859B2 (ja) 2021-12-08
AU2016261913B2 (en) 2021-08-12
US20180125928A1 (en) 2018-05-10
TW202231294A (zh) 2022-08-16
NZ737043A (en) 2025-02-28
JOP20160092B1 (ar) 2023-03-28
EP3294320A1 (en) 2018-03-21
CA2985777A1 (en) 2016-11-17
IL255527A (en) 2018-01-31
TWI762444B (zh) 2022-05-01
JP2021191755A (ja) 2021-12-16
EP3294320A4 (en) 2018-12-26
KR20180006437A (ko) 2018-01-17
AU2021258087B2 (en) 2023-04-27
IL255527B (en) 2021-07-29

Similar Documents

Publication Publication Date Title
AU2021258087B2 (en) Treatment of beta-thalassemia using ActRII ligand traps
AU2021212084B2 (en) Activin-ActRII antagonists and uses for treating anemia
US20230293634A1 (en) Activin-actrii antagonists and uses for treating bone and other disorders
CN111050770A (zh) 治疗骨髓增生性肿瘤相关的骨髓纤维化和贫血的方法
CN113604550A (zh) 用于治疗贫血症的生物标志物
KR20230010641A (ko) ACTRIIB 리간드 트랩 및 mTOR 억제제를 사용한 빈혈 치료 방법 및 조성물
KR20230003502A (ko) Actriib 리간드 트랩 및 페드라티닙을 사용한 빈혈 치료 방법
HK1248807B (zh) 激活素-actrii拮抗剂及用於治疗贫血症的用途